SU2C Canada Metastatic Breast Cancer Dream Team: Targeting mRNA Translation to Effectively Treat Metastatic Breast Cancer
Michael N. Pollak, MD
Jewish General Hospital
Nahum Sonenberg, PhD
The Dream Team is testing a new, small-molecule inhibitor of the kinases MNK1 and MNK2, two enzymes that are key regulators of the messenger RNA (mRNA) translation process. The inhibitor works against the proteins needed for aggressive, metastatic behavior and may also help the body’s immune system fight the cancer. The agent being tested, eFT508 (tomivosertib), is known to inhibit the translational process but has not yet been applied to metastatic breast cancer. This first-in-human study is administering this novel treatment in combination with paclitaxel or nab-paclitaxel to metastatic breast cancer patients for whom the standard of care has not been effective, in the hope that it will halt or slow the metastatic process.
Dream Team has treated first metastatic breast cancer patient with tomivosertib.